scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1029544380 |
P356 | DOI | 10.1186/S12943-015-0310-8 |
P932 | PMC publication ID | 4392793 |
P698 | PubMed publication ID | 25889301 |
P50 | author | Emily Hams | Q54378130 |
Derek J. Richard | Q55163299 | ||
Kathy Gately | Q58895237 | ||
Steven G Gray | Q38325510 | ||
Martin Barr | Q42762920 | ||
Padraic G. Fallon | Q42944857 | ||
P2093 | author name string | Anthony Mitchell Davies | |
Graham P Pidgeon | |||
Kenneth J O'Byrne | |||
P2860 | cites work | Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth | Q24293042 |
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor | Q24321564 | ||
Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect | Q24564247 | ||
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity | Q24677555 | ||
Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1 | Q28140309 | ||
Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells | Q28203964 | ||
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells | Q28209907 | ||
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding | Q28646414 | ||
A peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1-expressing breast tumour cells | Q29543360 | ||
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
Targeting neuropilin 1 as an antitumor strategy in lung cancer. | Q30833416 | ||
Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration | Q33523441 | ||
Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes | Q33940345 | ||
Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma | Q34157370 | ||
Non-angiogenic functions of VEGF in breast cancer | Q34559451 | ||
A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours | Q59059617 | ||
cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis | Q79801048 | ||
Neuropilin-1 expression in cancer and development | Q82183407 | ||
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth | Q35826030 | ||
Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells | Q36615085 | ||
Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes | Q37661416 | ||
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer | Q38062459 | ||
Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. | Q40155967 | ||
Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract | Q40563679 | ||
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer | Q43202368 | ||
Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. | Q45934563 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P2507 | corrigendum / erratum | Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer | Q92972114 |
P921 | main subject | lung cancer | Q47912 |
endothelium | Q111140 | ||
P304 | page(s) | 45 | |
P577 | publication date | 2015-02-20 | |
P1433 | published in | Molecular Cancer | Q15724585 |
P1476 | title | Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer | |
P478 | volume | 14 |
Q39794263 | A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery |
Q38621453 | Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. |
Q40979902 | Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model |
Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
Q92617919 | Changes in the coelomic microclimate during carbon dioxide laparoscopy: morphological and functional implications |
Q39066439 | Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer |
Q92972114 | Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer |
Q94471894 | Correlation of gene polymorphisms of vascular endothelial growth factor with grade and prognosis of lung cancer |
Q42374239 | Genetic status of KRAS modulates the role of Neuropilin-1 in tumorigenesis |
Q47114407 | MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells. |
Q37671418 | MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma |
Q100958900 | Mutations and mechanisms of WNT pathway tumour suppressors in cancer |
Q37108582 | NFAT5/STAT3 interaction mediates synergism of high salt with IL-17 towards induction of VEGF-A expression in breast cancer cells |
Q47401187 | NRP1-positive lung cancer cells possess tumor-initiating properties. |
Q97073461 | Nei Endonuclease VIII-like 2 Gene rs8191670 Polymorphism affects the Sensitivity of Non-small Cell Lung Cancer to Cisplatin by binding with MiR-548a |
Q36489958 | Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors |
Q64106137 | Neuropilin-1 is associated with the prognosis of cervical cancer in Henan Chinese population |
Q47825349 | Neuropilin-1 regulated by miR-320 contributes to the growth and metastasis of cholangiocarcinoma cells. |
Q89312213 | Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies |
Q64075896 | OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling |
Q28384920 | Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model |
Q61809661 | Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells |
Q38618616 | Rational, computer-enabled peptide drug design: principles, methods, applications and future directions. |
Q38714621 | Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881. |
Q26766306 | Significance and therapeutic implications of endothelial progenitor cells in angiogenic-mediated tumour metastasis |
Q42877991 | Structural optimization and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential VEGFR-2/PDGFRβ inhibitors. |
Q57471010 | Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models |
Q91620717 | Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update |
Q90399257 | The miR-141/neuropilin-1 axis is associated with the clinicopathology and contributes to the growth and metastasis of pancreatic cancer |
Q47918409 | VEGF as a potential target in lung cancer |
Q38826861 | VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach |
Search more.